Nima peanut sensor

Nima has been awarded a phase 2 Small Business Innovation Research grant from the National Institutes of Health to aid in continued research and development of Nima’s peanut sensor for consumers. The phase 2 funding amount released is more than $1,999,000, bringing total NIH funding for Nima peanut sensor R&D to more than $2.2 million.

The objective of this project is to develop and commercialize an economical, accurate, fast and portable device for peanut detection in foods, which can be readily used by consumers on a regular basis. It will provide peanut-sensitive consumers, parents of children with food sensitivities, health care providers, food manufacturers and restaurants with a means of testing foods to better verify food ingredients, thereby improving consumer health and quality of life.

The SBIR program is one of the largest sources of early-stage capital for innovative small companies in the United States. It allows U.S.-owned and operated small businesses to engage in federal research and development that has a strong potential for commercialization. A key objective of this work is “translating promising technologies to the private sector through strategic public and private partnerships, so that life-saving innovations reach consumer markets.”

The NIH SBIR program funds early stage small businesses that are seeking to commercialize innovative biomedical technologies. This competitive program helps small businesses participate in federal research and development, develop life-saving technologies and create jobs.

This is the fourth SBIR grant earned by Nima – NIH also awarded Nima an SBIR grant for the development of its gluten sensor totaling more than $1.2 million over two phases. Nima is committed to the long-term support of our community with research and development efforts to add new capabilities and products.


Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R44AI124907. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.